Molecular mechanism of Androgen Receptor mediated transcription
雄激素受体介导转录的分子机制
基本信息
- 批准号:10279240
- 负责人:
- 金额:$ 33.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-08 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAddressAffectAndrogen ReceptorBindingBiologyC-terminalCellsComplexComputer AnalysisCryoelectron MicroscopyDNADNA BindingDNA StructureData CollectionDevelopmentDiabetes MellitusDimerizationDiseaseDrug TargetingDrug resistanceEP300 geneEstrogen ReceptorsFamilyFoundationsFutureGene ExpressionGenesGenetic TranscriptionGoalsHeterogeneityHormonalHormonesHypogonadismImaging TechniquesKnowledgeLengthLigand Binding DomainLigandsLocationMalignant NeoplasmsMalignant neoplasm of prostateMediatingMolecularMolecular ConformationMonoclonal AntibodiesMutagenesisMutationN-terminalNuclear Hormone ReceptorsNuclear ReceptorsPathway interactionsPatientsPatternPhenotypePlayProteinsRNA SplicingReceptor ActivationRecombinantsRegulationResearch PersonnelResistanceResolutionResponse ElementsSiteStructureSystemTechniquesTestingTransactivationTranscription ProcessTranscriptional ActivationTranscriptional RegulationVariantWorkandrogen sensitivebasecomputerized data processingdesigndimereffective therapyexperimental studyhormone binding proteinhormone deficiencyimage processingimprovedinnovationinsightlarge scale datalipophilicitymalemembermultidisciplinaryparticlepromoterprotein protein interactionrecruitsmall molecular inhibitortargeted treatmenttherapeutic targettranscription factor
项目摘要
Abstract
Transcription factors are key determinants of gene expression. Lipophilic hormonal ligands and accompanying
co-regulatory molecules trigger the activity of transcription factors, including members of the nuclear hormone
receptor (NR) family. AR and its splice variant AR-V7 are NRs that play key roles in prostate cancer development,
and particularly CRPC. Current therapies targeting AR mainly focus on its ligand-binding domain (LBD), which
is not present in AR-V7. Patients that respond initially to those therapies become resistant to them within a few
years. Both AR and AR-V7 must recruit CoRs to be functionally active. Disruption of the AR–CoR interface
inhibits AR activity in both androgen-dependent cells and CRPC cells. Therefore, knowledge of how AR variants
interact with specific CoRs to form a transcriptionally active complex is critical for the design of therapeutics
targeting AR and AR-V7. Our preliminary studies provided the first structural understanding of active NR–CoR
complex assembly and demonstrated that conformational variability has a profound impact on NR-mediated
transcriptional activation.
In this proposal, we hypothesize that AR and its variants have a common set of CoRs, but that the assembly and
three-dimensional arrangement of those CoRs in AR complexes are unique to each and contribute to the
regulation of transcriptional activities. We propose to leverage the complementary expertise of investigators in
NR biology, cryoEM, and image processing to determine the structural basis of transcriptionally active AR
complexes. We will pursue that goal through two specific aims: 1) Solve a high-resolution DNA–AR structure to
identify domain-domain interactions in detail and then compare it to the structure of DNA–AR-V7; and 2) Improve
the resolution of AR–CoR complexes structures to identify detailed interactions and determine the structural
differences in comparison with AR-V7–CoR complexes. Both aims will utilize cryoEM to visualize functional AR–
CoR complexes. The proposed work is significant because the structures will describe the overall interactions in
the system to determine which components should be targeted for therapeutic modulation. A structural
understanding of how AR forms functional dimers and interacts with CoRs to activates gene expression will
provide critical information about the biology of transcription and enable future studies of looking for small-
molecular inhibitors can affect the AR complex arrangement. The proposed multidisciplinary work is innovative
because it employs advanced imaging techniques to achieve unprecedented insights into the structure and
function of AR–CoR complexes, AR heterodimers, and the drugs that target them.
摘要
转录因子是基因表达的关键决定因素。亲脂性激素配体和伴随的
共调节分子触发转录因子的活性,包括核激素的成员
受体(NR)家族。AR及其剪接变体AR-V7是在前列腺癌发展中起关键作用的NR,
尤其是CRPC。目前靶向AR的疗法主要集中在其配体结合结构域(LBD),
在AR-V7中不存在。最初对这些疗法有反应的患者在几分钟内就会对它们产生抗药性。
年AR和AR-V7都必须招募CoR才能发挥功能。AR-CoR接口中断
抑制雄激素依赖性细胞和CRPC细胞中的AR活性。因此,了解AR变异
与特异性CoR相互作用形成转录活性复合物对于治疗剂的设计至关重要
针对AR和AR-V7我们的初步研究提供了活性NR-CoR的第一个结构理解
复杂的组装,并证明构象变异性对NR介导的
转录激活
在这个提议中,我们假设AR及其变体具有一组共同的CoR,但是组装和
AR复合物中这些CoR的三维排列对每一种都是独特的,并有助于
转录活性的调节。我们建议利用调查人员的互补专长,
NR生物学、cryoEM和图像处理以确定转录活性AR的结构基础
配合物我们将通过两个具体目标来实现这一目标:1)解决高分辨率DNA-AR结构,
详细鉴定结构域-结构域相互作用,然后将其与DNA-AR-V7的结构进行比较;以及2)改进
AR-CoR复合物结构的解析,以识别详细的相互作用并确定结构
与AR-V7-CoR复合物相比,这两个目标都将利用cryoEM来可视化功能性AR-
CoR复合物。拟议的工作是有意义的,因为结构将描述整体的相互作用,
该系统用于确定哪些组分应该被靶向用于治疗调节。结构
了解AR如何形成功能性二聚体并与CoRs相互作用以激活基因表达,
提供有关转录生物学的关键信息,并使未来的研究能够寻找小的-
分子抑制剂可以影响AR复合物的排列。拟议的多学科工作具有创新性
因为它采用了先进的成像技术,以实现前所未有的洞察结构,
AR-CoR复合物、AR异二聚体和靶向它们的药物的功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zhao Wang其他文献
Zhao Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zhao Wang', 18)}}的其他基金
Investigation of the Cellular and Molecular Mechanisms of Thrombocyte Integrin Signaling
血小板整合素信号传导的细胞和分子机制研究
- 批准号:
10616738 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Role of de novo pyrimidine biosynthesis in pathological cardiac remodeling
从头嘧啶生物合成在病理性心脏重塑中的作用
- 批准号:
10579222 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Investigation of the Cellular and Molecular Mechanisms of Thrombocyte Integrin Signaling
血小板整合素信号传导的细胞和分子机制研究
- 批准号:
10421216 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Role of de novo pyrimidine biosynthesis in pathological cardiac remodeling
从头嘧啶生物合成在病理性心脏重塑中的作用
- 批准号:
10364407 - 财政年份:2022
- 资助金额:
$ 33.6万 - 项目类别:
Molecular mechanism of Androgen Receptor mediated transcription
雄激素受体介导转录的分子机制
- 批准号:
10810416 - 财政年份:2021
- 资助金额:
$ 33.6万 - 项目类别:
Molecular mechanism of Androgen Receptor mediated transcription
雄激素受体介导转录的分子机制
- 批准号:
10447691 - 财政年份:2021
- 资助金额:
$ 33.6万 - 项目类别:
Molecular mechanism of Androgen Receptor mediated transcription
雄激素受体介导转录的分子机制
- 批准号:
10612440 - 财政年份:2021
- 资助金额:
$ 33.6万 - 项目类别:
Role of the Xbp1s/GFAT1 axis in pathological cardiac remodelling
Xbp1s/GFAT1 轴在病理性心脏重塑中的作用
- 批准号:
9362022 - 财政年份:2017
- 资助金额:
$ 33.6万 - 项目类别:
Role of the Xbp1s/GFAT1 axis in pathological cardiac remodelling
Xbp1s/GFAT1 轴在病理性心脏重塑中的作用
- 批准号:
10170415 - 财政年份:2017
- 资助金额:
$ 33.6万 - 项目类别:
Role of the Xbp1s/GFAT1 axis in pathological cardiac remodelling
Xbp1s/GFAT1 轴在病理性心脏重塑中的作用
- 批准号:
10584092 - 财政年份:2017
- 资助金额:
$ 33.6万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 33.6万 - 项目类别:
Research Grant